Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer

The primary objective of this study is to determine the efficacy of metformin as a repurposed agent in human epidermal growth factor receptor 2 (HER2) positive breast cancer when added to

her1
ejection fraction
ductal carcinoma
cancer
measurable disease
  • 85 views
  • 14 Dec, 2021
  • 6 locations
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

This phase III trial aims to compare the efficacy and safety of fulvestrant or capecitabine as maintenance therapy after first-line chemotherapy in hormone receptor-positive, human epidermal

kidney function tests
epidermal growth factor receptor
capecitabine
HER2
growth factor
  • 5 views
  • 26 Feb, 2022
  • 7 locations
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2

progesterone
estrogen receptor
epidermal growth factor receptor
progesterone receptor
erbb2
  • 0 views
  • 02 Aug, 2021
  • 1 location
  • 0 views
  • 22 Apr, 2022
  • 11 locations
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician choice standard treatment in participants with human epidermal growth factor

apatinib
erbb2
metastatic gastric cancer
HER2
paclitaxel
  • 0 views
  • 22 Mar, 2022
  • 49 locations
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth

  • 0 views
  • 22 Mar, 2022
  • 1 location
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

This is a multicenter, single-arm phase II clinical trial to evaluate the efficacy and safety of RC48 in metastatic human epidermal growth factor receptor 2 (HER2) expressing breast cancer with

  • 0 views
  • 30 Apr, 2022
  • 3 locations
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

This is an open-label, single-arm, phase I trial. It is designed with a conservative dose escalation plan to ensure patient's safety and with a strong translational component to inform if target inhibition is achieved. With concerns regarding safety, based on extensive available pharmacokinetic data and clinical efficacy experience, bosutinib will …

aromatase inhibitor
palbociclib
oophorectomy
bone metastases
hormone therapy
  • 1 views
  • 23 Mar, 2022
  • 1 location
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

to treat hormone receptor-positive/human epidermal growth factor receptor 2-negative locally advanced breast cancer or metastatic breast cancer. This brings more treatment options for hormone

locally advanced breast cancer
EGFR
epidermal growth factor receptor
aromatase inhibitor
palbociclib
  • 0 views
  • 31 Jul, 2021
  • 3 locations
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

advanced or metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer and HER2-positive advanced breast cancer with liver metastasis.

locally advanced breast cancer
EGFR
her1
epidermal growth factor receptor
capecitabine
  • 135 views
  • 10 Mar, 2022
  • 67 locations